An interventional study of conscious sedation and General Anesthesia (control group) in Atrial Fibrillation (Paroxysmal), sponsored by Beijing Anzhen Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.
Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 19th largest by planned enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2026, is one of 21 with no phase, reaches primary completion later than 5 of the 25 other live ones, and was the 32nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 80+
Beijing Anzhen Hospital · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18–75
Beijing Anzhen Hospital · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 224 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 410 across the 24 interventional studies, 7,000 across the 12 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Anzhen Hospital is the lead sponsor of 194 studies on the registry; 103 are open to participants now.
6 of the studies in Atrial Fibrillation by Beijing Anzhen Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07411170Beijing Anzhen HospitalWearable Device-Assisted Remote Management in Atrial Fibrillation Complicated by Heart Failure: WARM-HF Trial | 2026-12 |
| NCT07541339Beijing Anzhen HospitalSafety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation | 2026-12-01 |
| NCT06791629Beijing Anzhen HospitalPulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation | 2026-12-15 |
| NCT06927908Beijing Anzhen HospitalCardiac Denervation in Aortic Arch Replacement | 2027-01-01 |
| NCT07095959Beijing Anzhen HospitalMarshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation | 2027-07-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the safety and efficacy of conscious sedation and general anesthesia in patients with paroxysmal atrial fibrillation undergoing their first pulsed-field ablation (PFA) procedure. It will also establish a scalable conscious sedation protocol for PFA. The main questions it aims to answer are:
Participants will:
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, which severely impairs patients' quality of life and is closely associated with an elevated risk of complications including thromboembolism and heart failure. Rhythm control, particularly catheter ablation, has become a cornerstone of AF management. In recent years, pulsed-field ablation (PFA) has emerged as a novel catheter ablation technique for AF. It demonstrates non-inferior ablation efficacy to conventional radiofrequency ablation, with the advantages of minimal injury to peri-myocardial tissues, high procedural efficiency and a low incidence of complications, thus serving as a promising alternative for AF catheter ablation.
Unlike radiofrequency ablation, PFA delivers high-voltage electric fields during the procedure, for which local anesthesia fails to achieve satisfactory sedation and analgesia. General anesthesia (GA) is currently the main anesthetic approach for PFA to ensure adequate intraoperative immobilization and provide stable conditions for precise procedural manipulation. However, GA has notable limitations: first, the central inhibitory effects of general anesthetics and procedural stress-induced responses are prone to cause perioperative hemodynamic instability, leading to adverse events such as hypotension and hypoxemia, which not only increase procedural risks but also exert adverse impacts on short- and long-term patient prognosis; second, GA usually requires endotracheal intubation or laryngeal mask ventilation, which may cause retropharyngeal injury and raise the risk of complications like bleeding or hematoma; third, GA incurs relatively high medical costs, further increasing the economic burden on patients.
In light of these unmet clinical needs, several observational studies have demonstrated the feasibility of deep or conscious sedation during PFA procedures. Nevertheless, sedation strategies vary across centers, and most findings are based on single-center, small-sample empirical summaries, lacking high-quality evidence from large-sample, rigorously designed randomized controlled trials (RCTs). Our team has previously explored a conscious sedation strategy in over 200 patients, and the results showed that this strategy could achieve satisfactory sedation and analgesia for PFA, significantly reduce the risk of GA-related hemodynamic instability, and yield favorable postoperative feedback from patients.
Given the sufficient evidence supporting the efficacy and safety of PFA in the treatment of paroxysmal atrial fibrillation (PAF), this study intends to conduct a single-center, 1:1 randomized, single-blind controlled trial to compare the safety and efficacy of conscious sedation and GA in PFA for PAF, aiming to provide an evidence-based basis for the selection of an optimal sedation regimen for PFA procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A conscious sedation regimen based on remimazolam combined with fentanyl, plus lidocaine for antitussive therapy, administered by electrophysiologists.
Procedure: conscious sedation
The general anesthesia group adopted a standardized general anesthesia process of remimazolam + sufentanil + rocuronium for anesthesia induction, and remimazolam + remifentanil for anesthesia maintenance.
Procedure: General Anesthesia (control group)
Medications: Remimazolam toluenesulfonate injection (25 mg) + Fentanyl citrate injection (0.1 mg) + Lidocaine (100 mg). Administration method: Remimazolam: 2 vials mixed with 50 mL of 0.9% sodium chloride injection to prepare a solution with a concentration of 1 mg/mL. The target Bispectral Index (BIS) is 60-80, and the infusion rate of remimazolam is adjusted according to the BIS and patient responses. Fentanyl citrate: 5 vials mixed with 50 mL of 0.9% sodium chloride injection to prepare a solution with a concentration of 0.01 mg/mL. Dose reduction and slower injection rate are required for patients with hepatic/renal insufficiency, obesity, or elderly/weak conditions.
After femoral vein puncture, anesthesia induction was performed with remimazolam (0.2-0.3 mg/kg), sufentanil (0.3-0.4 μg/kg) and rocuronium (0.6 mg/kg) following standard monitoring and preoxygenation. A laryngeal mask airway was inserted upon loss of consciousness and adequate muscle relaxation, with lung-protective mechanical ventilation applied at tidal volume 6-8 mL/kg, respiratory rate 10-14 breaths/min, I:E 1:2, FiO₂ 60% and fresh gas flow 2-3 L/min to maintain PaCO₂ at 35-45 cmH₂O. Anesthesia was maintained with continuous intravenous ciprofol (0.4-1 mg/kg/h) and remifentanil (0.1-0.2 μg/kg/min) to keep BIS 60-80 and MAP \>70 mmHg, with vasoactive agents as needed. Anesthetics were discontinued before surgery end; the laryngeal mask airway was removed after the patient regained consciousness with satisfactory spontaneous breathing, and antagonistic drugs were used if necessary.
Also known as: general anesthesia
Primary outcome
persistent systolic blood pressure \<85 mmHg for more than 60 seconds, or persistent hypoxemia (SpO₂ \<85%) for more than 60 seconds.
Time frame: During procedure
Individual components of the primary composite endpoint
persistent systolic blood pressure \<85 mmHg for more than 60 seconds, or persistent hypoxemia (SpO₂ \<85%) for more than 60 seconds.
Time frame: During procedure
The number of occurrences of each component of the primary outcome
The number of occurrences of each component of the primary outcome: (1) Systolic blood pressure persistently below 85 mmHg for more than 60 sec; or (2) Persistent hypoxemia (SpO₂ \< 85%) for more than 60 seconds.
Time frame: During procedure
Sedation difficulty score
1-10; 1 = easiest, 10 = most difficult
Time frame: During procedure
Total procedure time
from femoral vein puncture to sheath removal
Time frame: During procedure
Left atrial dwell time
The duration that the catheter stays in the left atrium
Time frame: During procedure
Total number of ablations
The total number of ablation discharges
Time frame: During procedure
Total ablation duration
The total ablation discharge time
Time frame: During procedure
Fluoroscopy time
Fluoroscopy time
Time frame: During procedure
Radiation dose
Radiation dose
Time frame: During procedure
Acute pulmonary vein isolation rate
Acute pulmonary vein isolation rate
Time frame: During procedure
Arterial PaCO₂ immediately before discontinuation of sedation/anesthesia
Arterial PaCO₂ immediately before discontinuation of sedation/anesthesia
Time frame: During procedure
Operative Sedation Assessment Scale
Please ask the patient to recall how much pain they felt during the surgery?(0-10, the higher the score, the more severe the pain)
Time frame: 12-24 hours postoperatively
Atrial fibrillation recurrence at 30 days post-procedure
Atrial fibrillation recurrence at 30 days post-procedure
Time frame: Day30
Atrial fibrillation recurrence at 90 days post-procedure
Atrial fibrillation recurrence at 90 days post-procedure
Time frame: Day90
Atrial fibrillation burden at 90 days post-procedure
Use 3 days of electrocardiogram patch monitoring to assess the burden of atrial fibrillation(Atrial fibrillation burden (%) = Total duration of atrial fibrillation ÷ Effective monitoring duration × 100%)
Time frame: Day90
Serious adverse events
SAE refers to adverse reactions that meet any of the following criteria: * Death or life-threatening * Resulting in severe and permanent disability * Requiring hospitalization or prolonging hospital stay * Causing congenital abnormalities or birth defects in offspring * A significant medical event determined by the researcher to cause major harm or injury to the subject, which may require drug treatment or surgical intervention to prevent the occurrence of other conditions as defined by SAE (such as death, permanent disability, hospitalization, etc.).
Time frame: Day0-90
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 8 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.